Advertisement
Organisation › Details
Eufets GmbH
EUFETS GmbH, a subsidiary of BioNTech AG specializes in providing services in the area of development and manufacture of cell-based and gene-based therapeutics. EUFETS possesses comprehensive know-how in the development and production of stem cell preparations, retroviral vectors, and genetic modification of primary cells and cell lines. Since 1999, the company has been GMP-certified, and is meanwhile recognized as a leading producer of retroviral vectors for clinical trials worldwide. Since 2012, EUFETS has also added the GMP manufacturing of in vitro transcribed mRNA to its portfolio. *
Start | 1997-01-01 established | |
End | 2017-10-04 renamed | |
Group | BioNTech (Group) | |
Today | BioNTech Innovative Manufacturing Services GmbH | |
Successor | BioNTech Innovative Manufacturing Services GmbH | |
Industry | cell therapy | |
Industry 2 | contract manufacturing (biologicals) | |
Person | Kühlcke, Klaus (BioNTech 201309 Managing Director of Eufets GmbH) | |
Street | 66 Vollmersbachstr. | |
City | 55743 Idar-Oberstein | |
Tel | +49-6781-9855-0 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: | ||
Record changed: 2023-12-30 |
Advertisement
More documents for BioNTech (Group)
- [1] BioNTech SE. (2/8/24). "Press Release: BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs". Mainz & London....
- [2] BioNTech SE. (1/31/24). "Press Release: BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305". Mainz & Shanghai....
- [3] BioNTech SE. (1/22/24). "Press Release: BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer". Mainz & Shanghai....
- [4] WuXi Biologics. (1/11/24). "Press Release: WuXi Biologics Announces Research Service Agreement with BioNTech on Discovering Investigational Monoclonal Antibodies for Developing Next-Generation Therapeutic Product Candidates". Shanghai....
- [5] BioNTech SE. (1/9/24). "Press Release: BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference". Mainz....
- [6] CureVac N.V.. (12/19/23). "Press Release: CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE". Tübingen....
- [7] BioNTech SE. (12/18/23). "Press Release: BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda". Kigali....
- [8] Biotheus Inc.. (11/6/23). "Press Release: Biotheus Enters Into Strategic Partnership with BioNTech to Develop and Commercialize Bispecific Antibody Candidate Targeting PD-L1 and VEGF in Multiple Solid Tumor Indications". Zhuhai....
- [9] Bayer, Max [Fierce Biotech]. (11/6/23). "News: BioNTech Adds Bispecific Candidate, mRNA Delivery Startup as Cancer Work Takes Center Stage"....
- [10] BioNTech SE. (10/31/23). "Press Release: BioNTech to Present Clinical and Preclinical Data Updates Across Multiple Immuno-Oncology Programs at 2023 SITC Annual Meeting". Mainz....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top